PL3616696T3 - Kompozycja farmaceytczna do podawania doustnego zawierająca enzalutamid - Google Patents

Kompozycja farmaceytczna do podawania doustnego zawierająca enzalutamid

Info

Publication number
PL3616696T3
PL3616696T3 PL18791486.6T PL18791486T PL3616696T3 PL 3616696 T3 PL3616696 T3 PL 3616696T3 PL 18791486 T PL18791486 T PL 18791486T PL 3616696 T3 PL3616696 T3 PL 3616696T3
Authority
PL
Poland
Prior art keywords
enzalutamide
pharmaceutical composition
orally administrable
containing pharmaceutical
administrable
Prior art date
Application number
PL18791486.6T
Other languages
English (en)
Inventor
Yoshiaki Umemoto
Takatsune Yoshida
Sachie Namiki
Akira Takagi
Ryo Kojima
Toshiro Sakai
Shinsuke Oba
Hajime Aoki
Original Assignee
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc. filed Critical Astellas Pharma Inc.
Publication of PL3616696T3 publication Critical patent/PL3616696T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL18791486.6T 2017-04-28 2018-04-27 Kompozycja farmaceytczna do podawania doustnego zawierająca enzalutamid PL3616696T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017090300 2017-04-28
PCT/JP2018/017159 WO2018199282A1 (ja) 2017-04-28 2018-04-27 エンザルタミドを含有する経口投与用医薬組成物

Publications (1)

Publication Number Publication Date
PL3616696T3 true PL3616696T3 (pl) 2025-05-05

Family

ID=63920425

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18791486.6T PL3616696T3 (pl) 2017-04-28 2018-04-27 Kompozycja farmaceytczna do podawania doustnego zawierająca enzalutamid

Country Status (13)

Country Link
US (1) US12036315B2 (pl)
EP (1) EP3616696B1 (pl)
JP (1) JP7172997B2 (pl)
KR (1) KR102684756B1 (pl)
CN (1) CN110573153B (pl)
AU (1) AU2018256998B2 (pl)
CA (1) CA3060366A1 (pl)
ES (1) ES3018265T3 (pl)
MX (1) MX394857B (pl)
PL (1) PL3616696T3 (pl)
PT (1) PT3616696T (pl)
RU (1) RU2019138248A (pl)
WO (1) WO2018199282A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI673051B (zh) 2012-09-11 2019-10-01 美商梅維森前列腺療法有限責任公司 恩雜魯它脈(enzalutamide)之調和物
SG11202106839XA (en) 2018-12-27 2021-07-29 Asahi Chemical Ind Cellulose powder, use thereof, and tablets
JP7238509B2 (ja) * 2019-03-19 2023-03-14 三菱ケミカル株式会社 医薬錠剤
WO2021240206A1 (en) 2020-05-24 2021-12-02 Lotus International Pte. Ltd. Enzalutamide formulation
JP7414668B2 (ja) 2020-08-28 2024-01-16 信越化学工業株式会社 ポリビニルアルコール含有造粒物及び固形製剤
CN116406257A (zh) * 2020-10-28 2023-07-07 默克专利股份有限公司 用于提高难溶性活性药物成分的溶解度的药物组合物和方法
JP2024040951A (ja) * 2022-09-13 2024-03-26 東和薬品株式会社 アンドロゲン受容体アンタゴニストの固体分散体を含む薬学的組成物
EP4374853A1 (en) 2022-11-22 2024-05-29 Lotus Pharmaceutical Co., Ltd. Solid formulation of enzalutamide
KR20250058470A (ko) 2023-10-23 2025-04-30 케이원팜 주식회사 안정성과 용출특성이 향상된 신규 엔잘루타마이드 함유 조성물 및 이의 제조방법
WO2025125565A1 (en) 2023-12-13 2025-06-19 Krka, D.D., Novo Mesto Tablet comprising enzalutamide
KR20250100928A (ko) 2023-12-27 2025-07-04 케이원팜 주식회사 생체이용률이 개선된 엔잘루타마이드 약학 조성물 및 이의 제조방법
CN118001243B (zh) * 2024-01-31 2024-10-22 四川鲁徽制药有限责任公司 一种恩杂鲁胺口腔崩解片及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996019974A1 (en) 1994-12-27 1996-07-04 Kanebo, Ltd. Sustained-release preparation
JP4072597B2 (ja) * 1994-12-27 2008-04-09 ナムローゼ・フェンノートシャップ・オルガノン 持続性製剤
JPH10316576A (ja) 1997-05-13 1998-12-02 Nissui Pharm Co Ltd キトサン含有錠剤
RU2205191C1 (ru) 2001-12-27 2003-05-27 Институт синтетических полимерных материалов им. Н.С. Ениколопова РАН Способ получения аморфизованного поливинилового спирта
NZ564223A (en) 2005-05-13 2011-03-31 Univ California Diarylhydantoin compounds for treating hormone refractory prostate cancer
NZ596260A (en) 2006-03-29 2013-05-31 Univ California Diarylthiohydantoin compounds
JP5498387B2 (ja) * 2008-09-12 2014-05-21 第一三共ヘルスケア株式会社 変色が抑制された安定な医薬製剤
RU2554081C2 (ru) 2010-02-24 2015-06-27 Медивэйшн Простейт Терапьютикс, Инк. Способ синтеза соединений диарилтиогидантоина и диарилгидантоина
WO2012129551A1 (en) 2011-03-23 2012-09-27 Ironshore Pharmaceuticals & Development, Inc. Methods and compositions for treatment of attention deficit disorder
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
EP2674149B1 (en) * 2012-06-15 2017-10-04 Shin-Etsu Chemical Co., Ltd. Method of preparing composite granule comprising low-substituted hydroxypropyl cellulose and rapid release preparation
KR20150053963A (ko) 2012-09-11 2015-05-19 닥터 레디스 레보러터리즈 리미티드 엔잘루타마이드 다형태 및 그의 제조
TWI673051B (zh) * 2012-09-11 2019-10-01 美商梅維森前列腺療法有限責任公司 恩雜魯它脈(enzalutamide)之調和物
WO2014167428A2 (en) 2013-04-10 2014-10-16 Shilpa Medicare Limited Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide
JP6274641B2 (ja) 2013-09-13 2018-02-07 独立行政法人 国立印刷局 偽造防止媒体及びその作製方法
WO2015115453A1 (ja) 2014-01-30 2015-08-06 テイカ製薬株式会社 口腔内速崩壊性固形製剤用組成物
CN106102716A (zh) 2014-02-05 2016-11-09 斯洛文尼亚莱柯制药股份有限公司 雄激素受体拮抗剂的固体药物组合物
EP3102188A4 (en) * 2014-02-05 2017-07-12 Merck Sharp & Dohme Corp. Novel disintegration systems for pharmaceutical dosage forms
WO2015163448A1 (ja) 2014-04-25 2015-10-29 中外製薬株式会社 4環性化合物を高用量含有する製剤
CN107205935A (zh) 2015-01-20 2017-09-26 默克专利股份有限公司 用聚乙烯醇作载体聚合物的化合物固体分散体
JP6403615B2 (ja) 2015-03-18 2018-10-10 日本酢ビ・ポバール株式会社 フィルムコーティング組成物並びに経口固形製剤及びその製造方法
JP2016056208A (ja) 2016-01-15 2016-04-21 日本酢ビ・ポバール株式会社 フィルムコーティング組成物並びに経口固形製剤及びその製造方法

Also Published As

Publication number Publication date
RU2019138248A (ru) 2021-05-28
JPWO2018199282A1 (ja) 2020-03-12
CA3060366A1 (en) 2018-11-01
CN110573153A (zh) 2019-12-13
JP7172997B2 (ja) 2022-11-16
EP3616696A1 (en) 2020-03-04
US12036315B2 (en) 2024-07-16
MX394857B (es) 2025-03-24
EP3616696A4 (en) 2021-01-27
AU2018256998B2 (en) 2023-11-09
MX2019012757A (es) 2019-12-16
KR20190137920A (ko) 2019-12-11
AU2018256998A1 (en) 2019-12-05
ES3018265T3 (en) 2025-05-14
EP3616696B1 (en) 2025-03-05
RU2019138248A3 (pl) 2021-07-21
PT3616696T (pt) 2025-04-03
WO2018199282A1 (ja) 2018-11-01
US20200146977A1 (en) 2020-05-14
CN110573153B (zh) 2023-04-04
KR102684756B1 (ko) 2024-07-15

Similar Documents

Publication Publication Date Title
ZA202001037B (en) Novel orally administrable formulation
ZA201805802B (en) Orally administrable composition
PT3616696T (pt) Composição farmacêutica administrável oralmente contendo enzalutamida
IL271657A (en) medical preparation
IL271986B1 (en) pharmaceutical preparation
GB201712159D0 (en) Pharmaceutical composition
GB201705303D0 (en) Pharmaceutical compositions
HUE068810T2 (hu) Gyógyászati készítmény
GB201804548D0 (en) Pharmaceutical compositions
GB201705304D0 (en) Pharmaceutical compositions
SG11202001179YA (en) Pharmaceutical compositions
IL272419A (en) Pharmaceutical composition
GB201719447D0 (en) Pharmaceutical composition
GB201705305D0 (en) Pharmaceutical compositions
GB201705306D0 (en) Pharmaceutical compositions
PL3646867T3 (pl) Kompozycja farmaceutyczna
GB201808571D0 (en) Pharmaceutical compositions
ZA202000014B (en) Pharmaceutical compositions
IL271513A (en) Innovative pharmaceutical composition
IL265436B (en) Pharmacy preparation
IL272044A (en) Pharmacy preparations
IL272428A (en) pharmaceutical preparations
GB201810109D0 (en) Pharmaceutical compositions
GB201809030D0 (en) Novel pharmaceutical uses
GB201715404D0 (en) Pharmaceutical compositions